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Background: Hepatocellular carcinoma (HCC) is among the most frequent human malignancies and a major cause
of cancer-related death worldwide. It is characterized by late detection and fast progression, and it is believed that
epigenetic disruption may be one of the molecular mechanisms leading to hepatocarcinogenesis. Previous studies
from our group revealed that HCC tumors exhibit specific DNA methylation signatures associated with major risk
factors and tumor progression. Imprinted genes are mono-allelically expressed in a parent-of-origin-dependent
manner and have been suggested to be more susceptible to deregulation in cancer. To test this notion, we performed
a targeted analysis of DNA methylation in known imprinted genes, using HCC samples and in vitro models of
carcinogenic exposure.
Results: Analysis of HCC DNA methylation in two independent datasets showed that differentially methylated
loci are significantly enriched in imprinted genes. Most of the promoters of imprinted genes were found
hypomethylated in HCC tumors compared to surrounding tissues, contrasting with the frequent promoter
hypermethylation observed in tumors. We next investigated the status of methylation of the imprinting control
region (ICR) of different imprinted clusters and found that the 15q11-13 ICR was significantly hypomethylated
in tumors relative to their surrounding tissues. In addition, expression of imprinted genes within this cluster was
frequently deregulated in a gene-specific manner, suggesting distinct mechanisms of regulation in this region. Finally,
primary human hepatocytes and hepatocyte-like HepaRG cells displayed higher methylation variability in certain
imprinted loci after natural hepatitis B virus (HBV) infection and after lipid accumulation, respectively.
Conclusion: The methylation status of a large panel of imprinted genes was found deregulated in HCC, suggesting a
major role of this mechanism during hepatocarcinogenesis. In vitro models support the hypothesis of imprinted gene
methylation as a potential marker of environmental exposures.
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Epigenetic mechanisms are believed to play a major role in
gene regulation during development and differentiation as
well as disease. Indeed, deregulation of gene expression due
to epigenetic events has been reported to play a role in car-
cinogenesis. The relative importance of epigenetics in defin-
ing the mammalian transcriptome in normal and disease* Correspondence: vargash@iarc.fr; herceg@iarc.fr
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unless otherwise stated.states is still unknown. However, the mammalian genome
contains a small number of genes for which epigenetic gene
regulation has been shown to play a major role in transcrip-
tional control, called imprinted genes. Genomic imprinting,
which results in the parental-specific expression of specific
genes, plays an important role in normal growth and devel-
opment [1]. To date, between 100 and 200 imprinted genes
have been described in mammals, many of them being well
conserved between mouse and human (http://www.har.
mrc.ac.uk/research/genomic_imprinting/, http://igc.otago.
ac.nz/home.html). Disruption of imprinting can result in al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to cancer [2]. Indeed, genomic imprinting subjects
mammals to a greater genomic risk because a muta-
tion in one allele (either genetic or epigenetic) can re-
sult in the absence of one or more gene products, thus
leading to a number of well-known imprinting disor-
ders, including Beckwith-Wiedemann, Silver-Russell,
Prader-Willi, and Angelman syndromes [3-5]. In can-
cer, loss of imprinting has been largely reported,
insulin-like growth factor 2 (IGF2) being the most
studied locus [6-8]. However, little is known about the
global control of imprinting regions in specific types
of human cancer.
Here, we were interested in the potential role of
imprinting deregulation in hepatocellular carcinoma
(HCC). HCC represents an endemic burden world-
wide, partially due to delayed diagnosis and multiple
risk factors that contribute to a permanent high inci-
dence [9,10], stressing the need to characterize poten-
tial new early biomarkers. Together with other liver
diseases, HCC represents a complex pathology due to
its heterogeneity in origin and outcome. Well-known
risk factors include chronic hepatitis B virus (HBV)
and hepatitis C virus (HCV) infection, steatohepatitis,
toxic, metabolic, and immune-related conditions [11].
Common to most of these risk factors is the establish-
ment of proliferative disease, frequently followed by
malignancy [12].
In the liver, the sequential progression to carcin-
oma has been linked to changes at the genetic and
epigenetic level, including aberrant induction of
pathways related to proliferation and development,
and inactivation of tumor suppressor genes [13,14].
Few studies have already reported disruption of
imprinted genes in HCC. Among them, the IGF2/
H19 cluster has been the most studied [15-17]. In
a similar way, delta-like 1 homolog (Drosophila)
(DLK1), a paternally expressed gene, has been found
to be upregulated in HCC tumors [18]. Deregulation
of IGF2, H19, and DLK1 has been shown to be associ-
ated with methylation changes and leading to cell
proliferation promotion while its interference triggers
inhibition of cell growth, colony formation, and
tumorigenicity in HCC cell lines [18], suggesting that
the deregulation of imprinted genes may promote can-
cer development.
Although the role of imprinted genes in carcinogenesis
is accepted, there are currently few data on their regu-
lation in tumors. Thus, we investigated the methyla-
tion status of a large panel of imprinted genes in HCC
tumors and surrounding tissues using two independ-
ent datasets. Using in vitro models of HCC risk
factors, we studied methylation variability in selected
imprinted loci.Results
DNA methylation profiling reveals enrichment at imprinted
loci in HCC
Our previous DNA methylation bead array analysis re-
vealed a strong panel of genes differentially methylated
in 38 HCC tumors compared with their matched sur-
rounding tissues [19], including genes already known
as deregulated in HCC like RASSF1A or APC [20,21]
(Figure 1A). Interestingly, this 244-CpG signature (corre-
sponding to 184 genes) comprises also other genes not
reported as deregulated in HCC. Thus, further analyses
of differentially methylated genes in HCC were per-
formed in order to better characterize the deregulation
associated with those epigenetic changes. A chromo-
somal location analysis of these genes revealed an
enrichment in specific chromosomes 7, 11, and 15
(Figure 1B). Indeed, 28% of differentially methylated
positions (DMPs) were comprised in those three chro-
mosomes. As chromosomes 7, 11, and 15 have been
all reported to contain clusters of imprinted genes, we
decided to test the overlap of our HCC signature with
a comprehensive list of 228 predicted or established
human imprinted genes (http://www.geneimprint.org/).
Out of a total of 813 genes analyzed (corresponding to
1,505 CpG sites), 59 imprinted genes (corresponding to
153 CpG sites) were present in the reference list. In this
sense, the GoldenGate bead arrays represent a biased se-
lection of cancer-related loci, including imprinted genes
(8.8% of all genes in the array consist of imprinted genes,
in contrast to approximately 1% described in the human
genome). Interestingly, an unsupervised clustering analysis
performed using only the 153 imprinted CpG sites re-
vealed that they are able to discriminate tumor samples
from surrounding tissues (Additional file 1: Figure S1).
When considering the differentially methylated genes in
the HCC tumor vs. surrounding comparison, we found 27
imprinted genes out of 184 total significant genes, more
than expected by chance (P = 0.0001, two-tailed Fisher’s
exact test). This significant enrichment was also observed
at the CpG site level, with 43 CpG sites in imprinted loci
out of a total of 244 sites (P = 0.0002, two-tailed Fisher’s
exact test). Differential methylation of imprinted genes in
HCC was found to be independent of tumor grade, stage,
and risk factor exposures (Figure 1C). In total, 28% of the
imprinted CpG sites analyzed by the array were found
significantly differentially methylated in HCC, relative to
surrounding tissues. Interestingly, most of them (79%)
were found hypomethylated in HCC tumors compared
with surroundings, including H19, MEST, and GABRA5,
contrasting with the common phenomenon of promoter
hypermethylation observed in tumors (Figure 1C).
GABRA5 promoter showed the highest fold change
reduction in methylation in tumors relative to adja-
cent tissues (5.16-fold change) (Table 1). Within the 9
Figure 1 (See legend on next page.)
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Figure 1 Imprinted genes are differentially methylated in HCC. (A) Volcano plot for the comparison of HCC tumors vs. adjacent tissues
(surrounding/tumor). The horizontal line defines the P value threshold of 0.001. Two representative hypermethylated (APC and RASSF1) and
hypomethylated (GABRA5 and MEST) genes are shown respectively in red and blue fonts. (B) Distribution of differentially methylated CpG sites
(n = 244) according to chromosomal location (blue bars). Reference proportion for all probes is shown as red bars. (C) Heatmap of differentially
methylated imprinted CpG sites (n = 43), with high methylation represented in red and low methylation in blue. Annotations in the lower
bars correspond to tumor vs. surrounding tissues, associated risk factors, and tumor stage. No data is shown for surrounding tissues (NA). (D)
Estimated proportion of imprinted genes in the total dataset (upper pie chart) and the differentially methylated CpG sites (lower pie chart).
Preferential maternal and paternal expressions are shown separately. (E) Validation of selected imprinted genes was assessed by pyrosequencing
using 5 tumor/surrounding pairs. *P value <0.05.
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5 were maternally expressed (KCNQ1, CDKN1C,
HOXA5, HOXA11, ASCL2) (Figure 1C, Table 1). The
original dataset includes 8.8% of imprinted genes, ma-
ternal and paternal origin being similarly represented
(Figure 1D). However, when discriminating imprinted
genes by their maternal or paternal contribution, we
found that most of the enrichment was due to differ-
ential methylation of paternally expressed genes, with
a representation of 3.8% of the total genes in the bead
array compared to 9.4% in the list of differentially
methylated genes (Figure 1D). Indeed, among the 43
significant imprinted loci, 9 are known to be associ-
ated with maternally expressed and 23 with paternally
expressed genes (Table 1), suggesting that the parental
origin of the gene may be related to its susceptibility
to epigenetic disruption in carcinogenesis.
In order to validate this data, we designed specific py-
rosequencing assays, allowing a quantitative measure-
ment of DNA methylation on several successive CpG
sites. We selected differentially methylated imprinted
genes located on different chromosomes and showing
opposite methylation profiles between tumors and sur-
rounding tissues (MEST, H19, and KCNQ1 as well as
GABRA5 promoters). Their methylation status was
assessed in five pairs of HCC samples. The four selected
regions displayed differential methylation, MEST, H19,
and GABRA5 being hypomethylated in tumors com-
pared with adjacent tissues, while KCNQ1 exhibited
hypermethylation of its promoter, confirming the bead
array data (Figure 1E).
In summary, differential methylation of imprinted
genes is a frequent finding in a series of HCC samples,
relative to their matched adjacent tissues. As a group,
they tend to be hypomethylated in HCC and their
methylation values are able to discriminate between tu-
mors and surrounding tissues. Moreover, paternally
imprinted genes are overrepresented in the set of differ-
entially methylated loci, relative to HCC surrounding
tissues.
Specific deregulation of the 15q11-13 ICR in HCC
The organization of imprinted genes within clusters al-
lows them to share common regulatory elements, suchas non-coding RNAs and differentially methylated re-
gions (DMRs). When these regulatory elements control
the imprinting of one or more genes, they are known as
imprinting control regions (ICRs) and exhibit specific
epigenetic features. Due to their key role in imprinting
regulation, we examined by pyrosequencing the methyla-
tion status of three well characterized ICRs (that were
found differentially methylated) in a small panel of HCC
tumors and related adjacent tissues (n = 5 pairs). The lo-
cations of those three ICRs were determined based on
previous reports [22-24]. The ICR controlling the
15q11-13 is composed of a sequence adjacent to the
SNRPN promoter (PWS-SRO) and a sequence located
35 kb upstream (AS-SRO) [24]. While no consistent
changes in DNA methylation were observed in MEST,
KCNQ1 ICR, and AS-SRO region in HCC tumors and
paired surroundings, a significant hypomethylation was
detected in HCC in PWS-SRO region (P value <0.005),
in agreement with the trend of methylation observed at
promoter regions (Figure 2A).
As the ICR is a key regulatory element for imprinted
genes, we next investigated the impact of the hypome-
thylation of the PWS-SRO ICR sequence (depicted in
Figure 2B) observed in HCC tumors on the expression
of the genes comprised in the 15q11-13 cluster. Two
genes, TJP1 and APBA2, reported as non-imprinted were
included as control. Most of the genes within the cluster
were found deregulated in HCC tumors compared with
surrounding tissues as assessed by quantitative real-time
PCR (qRT-PCR). While most of them were found re-
pressed in tumors (SNRPN, SNURF, TJP1, MKRN3),
GABRA5 and APBA2 were found upregulated in tumors
compared with adjacent tissues. No change of expression
was observed for GABRG3 and UBE3A (Figure 2C). The
loss of methylation observed at the promoter as well as
the ICR level is not fully reflected at the transcriptional
level within the cluster. Indeed, only GABRA5 and
APBA2 expression showed an inverse correlation with
ICR methylation data.
These data suggest that differential methylation of
imprinted genes in HCC is not necessarily linked to
differences in methylation in the corresponding ICRs.
However, the ICR of one important imprinted locus
(15q11-13) displays striking differential methylation in
Table 1 Imprinted genes differentially methylated in HCC tumors compared to surrounding tissues
Unique ID (CpG site) P value FDR Fold change Symbol Expressed allele
USP29_E274_F <1e-07 <1e-07 0.29 USP29 Unknown
MKRN3_P108_F 2E-07 5E-05 0.25 MKRN3 Paternal
ZIM3_E203_F 2E-07 5E-05 0.24 ZIM3 Unknown
GABRA5_E44_R 4E-07 7E-05 0.28 GABRA5 Paternal
ZIM3_P718_R 4E-07 7E-05 0.20 ZIM3 Unknown
MKRN3_E144_F 8E-07 0.0001 0.22 MKRN3 Paternal
PWCR1_E81_R 1E-06 0.0001 0.45 PWCR1 Paternal
GABRA5_P862_R 1E-06 0.0001 0.19 GABRA5 Paternal
GABRG3_E123_R 2E-06 0.0002 0.21 GABRG3 Paternal
TRPM5_E87_F 5E-06 0.0003 0.29 TRPM5 Paternal
TRPM5_P979_F 7E-06 0.0004 0.36 TRPM5 Paternal
GABRA5_P1016_F 1E-05 0.0006 0.34 GABRA5 Paternal
MEST_P62_R 2E-05 0.0009 0.32 MEST Paternal
ZIM3_P451_R 4E-05 0.0014 0.51 ZIM3 Unknown
TRPM5_P721_F 1E-04 0.0023 0.23 TRPM5 Paternal
SNRPN_P230_R 1E-04 0.0024 0.50 SNRPN Paternal
INS_P804_R 1E-04 0.0027 0.31 INS Paternal
GLI3_E148_R 3E-04 0.0043 0.55 GLI3 Maternal
CPA4_P1265_R 3E-04 0.0048 0.41 CPA4 Maternal
GFI1_E136_F 4E-04 0.0059 4.35 GFI1 Paternal
PWCR1_P811_F 6E-04 0.008 0.50 PWCR1 Paternal
CDKN1C_P626_F 0.001 0.0109 2.17 CDKN1C Maternal
ASCL2_P360_F 0.001 0.0111 4.35 ASCL2 Maternal
HOXA11_P698_F 0.001 0.0111 3.70 HOXA11 Maternal
DCN_P1320_R 0.001 0.0115 0.33 DCN Unknown
NDN_P1110_F 0.001 0.0126 0.39 NDN Paternal
FASTK_P598_R 0.001 0.0127 0.54 FASTK Maternal
MAGEL2_P170_R 0.002 0.0141 0.40 MAGEL2 Paternal
GNAS_P86_F 0.002 0.0148 0.53 GNAS Isoform dependent
HOXA5_E187_F 0.002 0.0157 2.44 HOXA5 Maternal
MEST_P4_F 0.002 0.016 0.33 MEST Paternal
DIO3_P674_F 0.002 0.0167 3.23 DIO3 Unknown
GNAS_E58_F 0.002 0.0167 0.40 GNAS Isoform dependent
ASB4_P52_R 0.002 0.017 0.37 ASB4 Unknown
NNAT_P544_R 0.002 0.0175 1.41 NNAT Paternal
MAGEL2_E166_R 0.003 0.0187 0.41 MAGEL2 Paternal
SNRPN_E14_F 0.003 0.0188 0.49 SNRPN Paternal
KCNQ1_P546_R 0.003 0.0198 1.85 KCNQ1 Maternal
USP29_P205_R 0.004 0.0252 0.53 USP29 Unknown
SNRPN_seq_18_S99_F 0.004 0.0261 0.50 SNRPN Paternal
GFI1_P208_R 0.004 0.0274 2.44 GFI1 Paternal
H19_P541_F 0.005 0.0289 0.46 H19 Maternal
ASB4_E89_F 0.005 0.029 0.53 ASB4 Unknown
FDR, false discovery rate.
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served at the ICR does not necessarily trigger an overex-
pression of genes within this region suggesting that
different regulatory mechanisms may be involved.
TCGA data analyses
The results described above suggest that aberrant
methylation of imprinted sites is a frequent finding in
HCC tissues, when comparing the methylation profiles
to their matched non-tumor tissues. To further valid-
ate this finding, we next analyzed the genome-wide
methylation data of an independent dataset consisting
of 47 HCC samples and their 47 matched surrounding
tissues (The Cancer Genome Atlas (TCGA) Data
Portal [https://tcga-data.nci.nih.gov/tcga/]). These samples
were processed with an alternative platform, the last ver-
sion of Illumina Infinium arrays (HM450) that interro-
gates the DNA methylation status of more than 450 K
sites across the human genome. Raw data files were down-
loaded from the TCGA repository and processed as
described in Methods. Methylation data was able to dis-
criminate most tumors from their surrounding tissues
(Figure 3A). Differential methylation between HCC and
surrounding tissues performed at the single site level
showed 1,328 DMPs (Additional file 2: Figure S2A).
Next, we studied the enrichment of imprinted loci
within those lists. As shown in Figure 3B, C, a subset of
30 imprinted sites (out of 1,328 differentially methylated
sites) were differentially methylated with the thresholds
used in this analysis (false discovery rate (FDR)-adjusted
P value <0.05, and change in methylation of at least
40%). Most of these sites were hypomethylated, as was
the case for our first dataset (Figure 1 and Additional file
3: Figure S2B). Although HM450 bead arrays have a
lower relative representation of imprinted loci when
compared to GoldenGate arrays (1.6% vs. 10.2% of all
sites, respectively), we also observed an enrichment of
these features in the list of differentially methylated sites
(from 1.6% to 2.3%, P value of Fisher’s exact test = 0.028)
(Figure 3D). Of note, there was also an increase in the
proportion of paternally expressed genes in the list of
DMPs, relative to the total imprinted sites contained in
the HM450 arrays (from 34% of imprinted sites in HM450
to 46% of the differentially methylated imprinted loci).
Analyses at the regional level identified 160 DMRs
when comparing tumor vs. surrounding tissues. Of the
160 HCC-related gene DMRs, there were 6 that corre-
sponded to known imprinted genes (that is, ASCL2,
ATP10A, DLX5, GATA3, NKX6-2, and OTX1). This is
three times more than expected by chance (P < 0.014,
hypergeometric test).
In summary, the analyses of a second dataset support
a significant enrichment of imprinted genes differentially
methylated in HCC. This confirms the findings of thefirst dataset performed in an independent series of sam-
ples and a different bead array format.
Imprinting methylation after in vitro risk factor exposure
of human hepatocytes
The results described above suggest that methylation of
imprinted loci is frequently lost in HCC. This finding
was independent of the risk factor associated to HCC
development (that is, HBV, HCV, alcohol). We therefore
sought to evaluate variations on DNA methylation levels
at imprinted loci using two in vitro models: natural HBV
infection of primary human hepatocytes (PHHs) and in-
duction of steatosis in hepatocyte-like HepaRG cells.
Our assumption was that methylation of imprinted loci
could be sensitive to exposure to either risk factor. In
the first case, we used PHH infected with HBV during
different time points. Infection was evident after 24 h
and up to 12 days, as assessed by qRT-PCR expression
of HBV X protein coding sequence (HBx) (Figures 3
and 4). DNA extracted from control and HBV-infected
conditions was used to quantify methylation in a panel
of imprinted or imprinted-related loci. No significant
differences were observed after 1 day of HBV infection
in any of the selected loci. However, MEST and GNAS
were transiently hypermethylated after 6 days of ex-
posure to HBV infection as assessed by pyrosequenc-
ing (Figure 3A).
In a similar way to HBV, we studied another risk factor
for HCC using an in vitro model of steatosis. We used
differentiated HepaRG cells to model steatosis progres-
sion, as previously described [25]. HepaRG cells were ex-
posed to increasing concentrations of oleate/palmitate
(O/P) to induce lipidic accumulation, as assessed by Nile
Red staining (Additional file 3: Figure S3A). Under these
conditions, 2 mM O/P was able to significantly in-
crease the methylation of GNAS promoter after 2 days
of exposure. There were no significant differences in
methylation for other imprinted loci (Additional file 3:
Figure S3B).
Together, these two in vitro models suggest that
imprinted loci may be susceptible to differential methy-
lation in response to environmental exposures related to
development of HCC.
Discussion
We have shown here that imprinted genes, as a group,
are able to discriminate HCC samples from their adja-
cent tissues. Indeed, differential methylation in HCC is
highly enriched in imprinted genes, especially those that
are paternally expressed. In one particular imprinted
cluster (15q11-13) differential methylation was extended
to the ICR and was associated with deregulated gene ex-
pression. We have also shown enrichment on differen-
tially methylated imprinted sites in an independent HCC
Figure 2 (See legend on next page.)
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Figure 2 Deregulation of the 15q11-13 cluster in HCC. (A) Pyrosequencing assays to assess Tumor vs. Surrounding methylation at imprinting
control regions (ICR) for MEST and KCNQ1 (n = 5 pairs). The ICR for the 15q11-13 cluster, composed of the Prader-Willi Syndrome region
(PWS-SRO) and the Angelman Syndrome region (AS-SRO), was also assessed. (B) Diagram of the 15q11-13 cluster showing the different
regions of study, including the ICR and two control non-imprinted (ni) genes (APBA2 and TJP1). (C) qRT-PCR for selected genes in the
15q11-13 cluster comparing tumors and adjacent tissues (n = 5 tumor/surrounding pairs). *P value <0.05.
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bead arrays. In addition, using in vitro models we show
that methylation of some imprinted loci may be more
sensitive to variation in response to known HCC risk
factors, such as HBV infection and lipidic accumulation.
Imprinting is defined as the parental allele-specific ex-
pression of a very limited set of genes. These genes play
a key role during embryonic development and adult
metabolism, and their expression is tightly regulated
allowing correct cell growth and proliferation. Indeed,
monoallelic expression of imprinting genes ensures that
the levels of proteins for which they encode are regu-
lated. The failure to precisely control their expression
may result in developmental abnormalities, as illustrated
by a number of hereditary overgrowth or neurological
syndromes, including Beckwith-Wiedemann syndrome.
This tight regulation depends on epigenetic marks,
mainly methylation marks established in a parental spe-
cific manner during embryogenesis. In normal somatic
cells, the stability of the marked regions is maintained
through each cellular replication by at least the DNA
methyltransferase DNMT1 during all our life. However,
a disruption of imprinting status, so-called loss of im-
printing (LOI) is frequently observed in a large number
of tumor types [26-30]. The high frequency of LOI as
well as its early emergence in tumors [31,32] makes LOI
detection an advantageous tool for early diagnosis and
detection. In this sense, non-cancer surrounding tissues
are known to accumulate DNA methylation changes.
However, as we have shown previously [19], the global
profile of DNA methylation from surrounding tissues is
closer to the profile of non-malignant liver adenoma
samples, as compared to HCC samples. This suggests
that aberrant DNA methylation progresses in intensity
from normal to surrounding and to malignant tissues.
Whether a similar pattern is observed for imprinting
genes would be an interesting subject for future re-
search. Importantly, the patterns of deregulated methyla-
tion at imprinted loci described in our manuscript are
independent of the putative etiology of the samples (that
is, HBV, HCV, or alcohol consumption).
Few studies have already reported disruption of
imprinted genes in HCC [18,33]. Among them, the
IGF2/H19 cluster has been the most studied [15-17].
In most normal adult tissues, only the paternal allele
of IGF2 is expressed, whereas only the maternal allele
of H19, which is located close to IGF2, is expressed. InHCC, this balance of expression is lost. Increased
expression of the IGF2 gene has been reported to be
associated with loss of adult-type promoter (P1) tran-
scription, re-imprinting of the fetal-type promoters
(P2 to P4), and expression of both alleles of the H19
gene [33-36]. Upregulation of IGF2 and H19 can
promote cell proliferation in liver cells. In the same
manner, delta-like 1 homolog (Drosophila) (DLK1), a
paternally expressed gene, has been found to be up-
regulated in HCC tumors. This significant increase of
DLK1 expression has been shown to be associated
with methylation changes and leading to cell prolifera-
tion promotion while its interference triggers inhib-
ition of cell growth, increased colony formation, and
tumorigenicity in HCC cell lines [18] suggesting that
the deregulation of imprinted genes may promote can-
cer development.
Here, for the first time, we identified a large panel of
imprinted genes altered in HCC. Indeed, a remarkable
number of imprinted promoters were found hypomethy-
lated in HCC tumors compared with surrounding tis-
sues, while only few of them that were hypermethylated.
Analyses on the specific 15q11-13 region revealed that
the changes at the imprinted promoter were correlated
with the loss of methylation observed also at the
imprinted control region (ICR), suggesting a more global
deregulation within this cluster. Maybe contrary to ex-
pectation, these changes at the methylation level are not
fully reflected at the transcriptional level. Indeed, most
of the genes within this cluster were found downregu-
lated in tumors compared to surrounding tissues with
the exception of the gene encoding for the GABA type-
A receptor alpha5 subunit, GABRA5, essential for fast
inhibitory neurotransmission and critical in brain func-
tion [37]. GABA(A) receptor alpha5 subunit has been
associated with autism and bipolar disorder [38,39] but
GABRA5 was never reported as deregulated in cancer.
We may hypothesize that the increase of GABRA5 ex-
pression observed can promote cancer development;
however, further analyses are needed. Failure to establish
a proper imprint of this region in humans has been
already described to result in the neurobehavioral disor-
ders, Prader-Willi syndrome (PWS) and Angelman syn-
drome (AS) [40]; however, this is the first time that an
association with cancer is established. In a similar way,
we show that the imprinted genes mesoderm specific
transcript (MEST) and G protein alpha stimulating
Figure 3 TCGA replication analysis. HM450 genome-wide methylation data was downloaded from TCGA (LIHC) for 47 available HCC tumor/surrounding
pairs (see Methods). (A) Multi-dimensional scaling (MDS) plot showing differential clustering of control vs. tumor tissues. (B) Differential methylation analysis
using paired (tumor/surrounding) linear regression identified 1,328 differentially methylated positions (DMPs); 30 sites (out of 1,328) corresponding to
known imprinted loci were used to build an unsupervised cluster. The corresponding heatmap shows the normalized methylation data in a blue-red scale
(from lower to higher methylation). Tumor grade is shown in the annotation panel as G1, G2, or G3. (C) Example plots of methylation data for 6 of the top
differentially methylated imprinted sites in the TCGA HCC tumor vs. surrounding comparison (n= 47 tumor/surrounding pairs). (D) Enrichment analysis
comparing the proportion of differentially methylated positions (DMPs) found in imprinted loci for dataset 1 (our original GoldenGate analysis) and dataset
2 (TCGA HM450 analysis). The barplot shows a significant enrichment in imprinted loci in both datasets. The data used to calculate enrichment and the
corresponding P values (Fisher’s exact test) are shown in the lower panel. *P value <0.05.
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Figure 4 In vitro models of risk factor exposure. Primary human hepatocytes were naturally infected with HBV. Efficiency was monitored by
qRT-PCR of HBx transcript (upper panel). DNA extracted at different time points was used for pyrosequencing analysis of selected imprinted regions
comparing mock to HBV-infected hepatocytes (lower panels).
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to differential methylation in response to specific risk
factors, although further studies will be required to define
the kinetics and stability of those changes. In this sense,
our in vitro systems better reflect the response to acute ex-
posures. Long-term hepatocyte culture systems or animal
models would better define the kinetics of imprinting de-
regulation under specific environmental exposures.
Conclusions
In summary, we report the HCC-dependent hypomethy-
lation of a large panel of imprinted genes and replicate this
finding in an independent dataset. There is a remarkable
bias between paternally and maternally imprinted genes
within differentially methylated loci. One of the most sig-
nificantly deregulated loci in HCC corresponds to the re-
gion controlled by the 15q11-13 ICR, which includes the
maternally imprinted GABRA5 gene.
Methods
Samples
All patients included in the study were referred for treat-
ment to Edouard Herriot Hospital in Lyon, France,
between 1997 and 2009, and have been previously
described [19]. Thirty-eight patients with HCC were se-
lected for analysis; in all cases, cryopreserved samples
from the primary tumor were available for study. In 30
patients, paired cryopreserved samples of adjacent non
malignant tissue were also available.
HBV infection model
HBV inocula were prepared as described [41]. Shortly,
HBV was concentrated from the supernatant of
HepG2.2.15 cells using centrifugal filter devices and
tittered by HBV-DNA dot blot analysis after sedimen-
tation into a CsCl density-gradient to determine envel-
oped DNA-containing viral particles. PHHs were isolated
from surgical liver resections, cultured, and infected with
HBV as described [42,43]. Infected PHH and correspond-
ing controls were kept for 1, 6, and 12 days. Supernatants
were obtained to validate the efficiency of infection by
ELISA, and nucleic acids were extracted for expression
and DNA methylation analyses.
Steatohepatitis model
HepaRG cells (6 × 104/well) were seeded in culture
six-well plates using William’s Medium E (Invitrogen,
Carlsbad, CA, USA) and incubated at 37°C, 5% CO2.
The medium was renewed every 3 days. Once a maximal
confluence was reached (85 to 100%), culture medium
was supplemented with EGF (90 ng/mL) during 1 week
then with EGF and 2% dimethyl sulfoxide (DMSO) for
another week to stimulate HepaRG cells differentiation.
Biological triplicates were then treated with 0.5 mM,1 mM, 2 mM O/P (2:1) (Sigma, St. Louis, MO, USA) in
differentiation medium. Cells were washed with PBS and
incubated with 100 nM Nile Red (Sigma) in the culture
medium 15 min at 37°C. Cells were fixed in 4% formal-
dehyde, washed twice with PBS and mounted on a slide
with a mounting medium containing DAPI for nuclear
counterstaining. Cells were analyzed using a fluorescence
microscope (Eclipse Ti, Nikon Instruments, Melville, NY,
USA) and images were taken using the NIS-Elements soft-
ware (NIS, Nikon Instruments).Beadarray analysis
Genomic DNA from all samples was treated with EZ
DNA methylation-Gold kit (Zymo Research, Irvine, CA,
USA), according to the manufacturer’s protocol to con-
vert genomic DNA. The modified DNA (20 to 25 ng/μL)
was stored at −20°C until use. The Illumina’s GoldenGate
HCC methylation dataset has been previously reported
[19,21]. Here, only the 153 CpG sites associated with
imprinted genes have been filtered (corresponding to 59
imprinted genes). BRBArrayTools software (version 3.8
beta2) was used for further analysis, using the M values
(Mi = log2(Betai/1 − Betai) as a transformation of the beta
values, as recommended [44]. CpG sites showing minimal
variation across the set of arrays were excluded from
the analysis. Class comparison was performed with the
BRBArrayTools software.Quantitative analysis of DNA methylation by
pyrosequencing
The methylation status was confirmed using pyrose-
quencing assays, as previously described [21]. DNA
amplifications, using specific biotinylated primers and
specific PCR conditions, were carried out on all modi-
fied DNA samples (Additional file 4: Table S1). Of modi-
fied DNA, 20 to 25 ng were amplified in a total volume
of 50 μL. Of PCR reaction, 10 μL were analyzed on agar-
ose gel whereas the remaining 40 μL were used in pyrose-
quencing assay (Qiagen, Venlo, Netherlands) according to
the manufacturer’s instructions.Quantitative RT-PCR
Total RNA was isolated using the TRIzol Reagent (Invi-
trogen) according to the manufacturer’s instructions.
Reverse transcription reactions were performed using
MMLV-RT (Invitrogen) and random hexamers, accord-
ing to the manufacturer’s protocol. Primers and probes
were designed using Universal Probe Library Assay
Design Center (Roche, Basel, Switzerland). qRT-PCR was
performed in triplicates of each condition, using FastStart
TaqMan Probe Master (Roche) and a MX3000P real-time
PCR system (Stratagene, San Diego, CA, USA).
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HCC methylome data (idat files) and their related clinical
data were obtained from TCGA Data Portal (https://
tcga-data.nci.nih.gov/tcga/). Correlation analyses on
DNA methylation and gene expression have been per-
formed using MethHC, a database for human pan-
cancer methylation and gene expression analyses [45].
Only complete datasets for DNA methylation and gene
expression available for both tumors and adjacent matched
non tumor samples were analyzed (47 cases). Data pre-
processing and analysis was performed using R/Bioconduc-
tor packages. Data quality was assessed using boxplots for
the distribution of methylated and unmethylated signals,
and multidimensional scaling plots and unsupervised
clustering were used to check for sample outliers. Cross-
reactive probes, probes mapping to sex chromosomes, and
probes overlapping with a single nucleotide polymorphism
(SNP) with an allele frequency of at least 5% in the overall
population were also removed, as previously described [46].
Type I and type II probe distributions were aligned using
intra-array beta-mixture quantile normalization [47].
Logarithmically transformed methylation values [44] were
interrogated for differential methylation between tumors
and matched surrounding tissues in a paired linear regres-
sion [48]. DMPs were selected based on a threshold for
the adjusted P value (FDR) of 0.05 and a difference in
methylation between groups (delta-beta) of at least 40%.
The bump hunting method was used to define DMRs
using the recommended proximity-based criteria [49].
Additional files
Additional file 1: Figure S1. Differential imprinted CpG methylation in
HCC. Heatmap of all imprinted CpG sites (n = 153), with high methylation
represented in red and low methylation in blue. The unsupervised clustering
is able to discriminate HCC tumors from adjacent tissues, as shown in the
lower bar annotation.
Additional file 2: Figure S2. TCGA data analysis. A. Heatmap of all
differentially methylated positions distinguishing HCC tissues from their
matched surrounding tissues (n = 1,328), with high methylation represented
in red and low methylation in blue. B. average methylation levels for a
selection of imprinted genes was plotted using MethHC (as described
in Methods). Tumors are shown in red, and non-tumor tissues are
shown in green.
Additional file 3: Figure S3. In vitro steatosis model. Lipid
accumulation in cells treated with Oleate/Palmitate (O/P). Lipid vacuole
accumulation was assessed after 48 h in control cells (A) and cells treated
with 0.5 mM (B), 1 mM (C), 2 mM (D) O/P (200×). Lipids were stained
with Nile red (red) and nuclei were counterstained with DAPI (blue)
(upper panel). DNA from these conditions was used to assess DNA
methylation by pyrosequencing of selected imprinted regions (lower
panels). (*) indicates P value <0.05.
Additional file 4: Table S1. Pyrosequencing assays. List of primers
(forward, reverse, and sequencing) used for bisulfite-pyrosequencing
assays of imprinted loci. ICR = imprinting control region.
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